You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

KENALOG-10 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kenalog-10 patents expire, and what generic alternatives are available?

Kenalog-10 is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in KENALOG-10 is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kenalog-10

A generic version of KENALOG-10 was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for KENALOG-10?
  • What are the global sales for KENALOG-10?
  • What is Average Wholesale Price for KENALOG-10?
Summary for KENALOG-10
Drug patent expirations by year for KENALOG-10
Drug Prices for KENALOG-10

See drug prices for KENALOG-10

Recent Clinical Trials for KENALOG-10

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Foundation for Orthopaedic Research and EducationPhase 1
Florida Orthopaedic InstitutePhase 1
Next Generation Regenerative Medicine LLCPhase 1/Phase 2

See all KENALOG-10 clinical trials

Pharmacology for KENALOG-10

US Patents and Regulatory Information for KENALOG-10

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Apothecon KENALOG-10 triamcinolone acetonide INJECTABLE;INJECTION 012041-001 Approved Prior to Jan 1, 1982 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 1 of 1 entries

Market Dynamics and Financial Trajectory for KENALOG-10

Introduction to KENALOG-10

KENALOG-10, a formulation of triamcinolone acetonide, is a long-acting corticosteroid injection used for its marked anti-inflammatory action. It is indicated for various medical conditions, including rheumatoid arthritis, osteoarthritis, and several dermatological disorders[2][3][4].

Market Indications and Uses

KENALOG-10 is widely used in several therapeutic areas:

  • Intra-Articular and Soft Tissue Administration: It is used as adjunctive therapy for acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis[2][3][4].
  • Intralesional Administration: It is indicated for conditions such as alopecia areata, discoid lupus erythematosus, keloids, and various inflammatory skin lesions[2][3][4].

Competitive Landscape

The corticosteroid market is highly competitive, with several other formulations and brands available. However, KENALOG-10 stands out due to its long-acting nature and specific indications. Competitors include other corticosteroid injections like methylprednisolone and prednisolone, but KENALOG-10's unique formulation and administration routes give it a niche market position[2][3].

Market Demand and Growth

The demand for KENALOG-10 is driven by the prevalence of the conditions it treats. For instance:

  • Rheumatoid Arthritis and Osteoarthritis: The increasing incidence of these conditions, particularly among the aging population, contributes to the growing demand for effective treatments like KENALOG-10[4].
  • Dermatological Conditions: The rising awareness and diagnosis of skin conditions such as psoriasis, alopecia areata, and keloids also boost the demand for intralesional corticosteroid treatments[2][3].

Financial Performance

The financial trajectory of KENALOG-10 is influenced by several factors:

  • Sales Revenue: KENALOG-10 generates significant revenue due to its widespread use in various medical specialties. The product's long-acting nature often leads to fewer injections needed compared to shorter-acting alternatives, which can impact pricing and revenue per patient[4].
  • Market Share: As a well-established brand, KENALOG-10 holds a substantial market share in the corticosteroid injection segment. This is due to its efficacy, safety profile, and the trust it has built among healthcare providers and patients[2][3].

Pricing and Reimbursement

The pricing of KENALOG-10 can vary based on the region, healthcare system, and insurance coverage. In general:

  • Cost-Effectiveness: Despite being a long-acting preparation, KENALOG-10 is often considered cost-effective due to the reduced need for frequent injections and the potential to avoid more invasive or costly treatments[2][3].
  • Reimbursement: KENALOG-10 is typically covered by various health insurance plans, which helps in maintaining its market presence and financial stability[5].

Regulatory Environment

The regulatory environment plays a crucial role in the financial trajectory of KENALOG-10:

  • Approval and Compliance: KENALOG-10 has been approved by regulatory bodies such as the FDA, and adherence to regulatory guidelines is essential for maintaining market approval and avoiding any financial penalties[2][3][4].
  • Safety and Efficacy Monitoring: Continuous monitoring of safety and efficacy data helps in ensuring that the product remains compliant with regulatory standards, which is vital for its financial performance.

Challenges and Risks

Several challenges and risks can impact the financial trajectory of KENALOG-10:

  • Side Effects and Contraindications: The product has several contraindications and potential side effects, such as increased risk of infections, visual disturbances, and systemic effects, which can affect its market acceptance and sales[1][2][3].
  • Competition from Generic Alternatives: The potential entry of generic versions of triamcinolone acetonide could pose a significant threat to the market share and revenue of KENALOG-10[5].

Future Outlook

The future outlook for KENALOG-10 is generally positive due to:

  • Increasing Prevalence of Target Conditions: The growing incidence of rheumatoid arthritis, osteoarthritis, and dermatological conditions will continue to drive demand for effective treatments like KENALOG-10[4].
  • Innovative Marketing Strategies: Continuous innovation in marketing and patient education can help maintain and expand the market share of KENALOG-10[4].

Key Takeaways

  • Market Indications: KENALOG-10 is used for a range of inflammatory conditions, including rheumatoid arthritis and various dermatological disorders.
  • Competitive Advantage: Its long-acting nature and specific administration routes give it a unique market position.
  • Financial Performance: Driven by sales revenue, market share, and cost-effectiveness.
  • Regulatory Compliance: Critical for maintaining market approval and avoiding financial penalties.
  • Challenges and Risks: Includes side effects, contraindications, and competition from generic alternatives.
  • Future Outlook: Positive due to increasing prevalence of target conditions and innovative marketing strategies.

FAQs

Q: What are the primary indications for KENALOG-10?

A: KENALOG-10 is indicated for intra-articular and soft tissue administration in conditions like acute gouty arthritis, rheumatoid arthritis, and osteoarthritis, as well as intralesional administration for various dermatological conditions[2][3][4].

Q: Is KENALOG-10 suitable for acute stress situations?

A: No, KENALOG-10 is not suitable for use in acute stress situations due to its long-acting nature[2][3].

Q: What are the common side effects of KENALOG-10?

A: Common side effects include increased risk of infections, visual disturbances, and systemic effects such as Cushing’s syndrome and adrenal suppression[1][2][3].

Q: Can KENALOG-10 be administered intravenously?

A: No, KENALOG-10 should not be administered intravenously due to the risk of serious adverse effects[1][2].

Q: How does the regulatory environment impact the financial performance of KENALOG-10?

A: Adherence to regulatory guidelines is crucial for maintaining market approval and avoiding financial penalties. Continuous monitoring of safety and efficacy data is essential for compliance[2][3][4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.